GF FUND MANAGEMENT CO. LTD.
Position in NAMS — NewAmsterdam Pharma Co N.V.
CIK 2057060
GUANGZHOU, F4
Position in NAMS
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$82,488
+$991 QoQ
Shares Held
2,434
-4.4% QoQ
Ownership
0.002%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#168
of 197 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026GF FUND MANAGEMENT CO. LTD. holds $72,227,940 across 200 Biotechnology names. NAMS ranks #56 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
62,678 | $31,134,042 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
25,824 | $16,102,296 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
29,770 | $8,961,663 | |
| 4 | INCY |
Incyte Corp
|
8,590 | $973,762 | |
| 5 | RVMD |
Revolution Medicines, Inc.
|
4,195 | $785,639 | |
| 6 | MRNA |
Moderna, Inc.
|
7,839 | $548,965 | |
| 7 | RPRX |
Royalty Pharma plc
|
9,065 | $508,274 | |
| 8 | ARGX |
Argenx SE
|
546 | $506,562 |
All Filings in NAMS
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $82,488 | 2,434 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $81,497 | 2,546 | Shares | Sole | 2026-04-15 | |
| 2025-12-31 | $78,158 | 2,228 | Shares | Sole | 2026-01-27 | |
| 2025-09-30 | $68,910 | 2,423 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $42,830 | 2,365 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $48,411 | 2,365 | Shares | Sole | 2025-04-29 | |
| 2024-12-31 | $49,858 | 1,940 | Shares | Sole | 2025-02-19 | |
| No filing history on record for this holder in this stock. | ||||||